Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome

Area of Science:

• Nephrology
• Immunology
• Clinical Trials

Background:

• Treatment-resistant nephrotic syndrome lacks effective FDA-approved therapies for proteinuria remission and kidney function preservation.
• CD80 (B7-1) expression on injured podocytes suggests a potential therapeutic target.
• Abatacept has shown promise in normalizing protein excretion and maintaining kidney function in preclinical and clinical studies.

Purpose of the Study:

• To design and conduct a randomized, placebo-controlled clinical trial of abatacept for treatment-resistant nephrotic syndrome.
• To evaluate the efficacy of abatacept in patients with focal segmental glomerulosclerosis or minimal change disease.
• To validate CD80 as a therapeutic target using a precision medicine approach.

Main Methods:

• A randomized, placebo-controlled, hybrid parallel-group/crossover (switchover) trial design.
• Participants will receive abatacept or placebo for 4 months per period.
• A projected sample size of 90 patients with 80% power to detect a 28% treatment difference.

Main Results:

• The primary outcome is a ≥50% reduction in urine protein:creatinine ratio to <3 within 4 months.
• The study is powered to detect a significant treatment difference.

Conclusions:

• This trial advances the validation of CD80 as a therapeutic target for treatment-resistant nephrotic syndrome.
• The study implements a precision medicine strategy by targeting the underlying disease mechanism.
• Results will inform future treatment strategies for this serious kidney condition.